Blockade of Effects of Smoked Marijuana by the CB1-Selective Cannabinoid Receptor Antagonist SR141716 | Zendy

Marilyn A. Huestis | Zendy; David A. Gorelick | Zendy; Stephen J. Heishman | Zendy; Kenzie L. Preston | Zendy; Richard Alan Nelson | Zendy; Eric T. Moolchan | Zendy; Richard Frank | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Blockade of Effects of Smoked Marijuana by the CB1-Selective Cannabinoid Receptor Antagonist SR141716

Author(s) -

Marilyn A. Huestis,

David A. Gorelick,

Stephen J. Heishman,

Kenzie L. Preston,

Richard Alan Nelson,

Eric T. Moolchan,

Richard Frank

Publication year - 2001

Publication title -

archives of general psychiatry

Language(s) - English

Resource type - Journals

eISSN - 1538-3636

pISSN - 0003-990X

DOI - 10.1001/archpsyc.58.4.322

Subject(s) - cannabinoid receptor , cannabinoid , antagonist , rimonabant , placebo , pharmacology , delta 9 tetrahydrocannabinol , cannabinoid receptor antagonist , blockade , medicine , psychology , receptor , alternative medicine , pathology

SR141716, a recently developed CB1 cannabinoid receptor antagonist, blocks acute effects of Delta-9-tetrahydrocannabinol (THC) and other CB1 cannabinoid agonists in vitro and in animals. These findings suggest that CB1 receptors mediate many of the effects of marijuana, but this has not been evaluated in humans.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research